Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Stenvang

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Expert Review of Anticancer Therapy|August 28, 2015
Drug transporters in breast cancer: response to anthracyclines and taxanesIben Kümler, Jan Stenvang, José Moreira, et al.
Breast Cancer Research and Treatment|October 25, 2006
Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cellsLisa B Frankel, Anne E Lykkesfeldt, Jens B Hansen, et al.
Seminars in Cancer Biology|February 26, 2008
The utility of LNA in microRNA-based cancer diagnostics and therapeuticsJan Stenvang, Asli N Silahtaroglu, Morten Lindow, et al.
Cancer Journal (Sudbury, Mass.)|June 1, 2012
The therapeutic potential of microRNAs in cancerStine B Thorsen, Susanna Obad, Niels F Jensen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 24, 2020
Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell lineAsbjørn Nøhr-Nielsen, Sofie Otzen Bagger, Nils Brünner, et al.
Cancers|April 25, 2020
An Explorative Analysis of <i>ABCG2/TOP-1</i> mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 TrialJan Stenvang, Eva Budinská, Eric van Cutsem, et al.
International Journal of Molecular Sciences|September 8, 2017
Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A ReviewDorte Lisbet Nielsen, Jesper Andreas Palshof, Nils Brünner, et al.
Molecular Cancer Therapeutics|June 19, 2007
Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell deathChristina Westmose Yde, Mads Gyrd-Hansen, Anne E Lykkesfeldt, et al.
Breast Cancer Research and Treatment|February 3, 2007
A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancerLouise M Rasmussen, Nurulain T Zaveri, Jan Stenvang, et al.
Cancer Letters|July 17, 2007
Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMATChristina Westmose Yde, Thomas Frogne, Anne E Lykkesfeldt, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Expert Review of Anticancer Therapy|August 28, 2015
Drug transporters in breast cancer: response to anthracyclines and taxanesIben Kümler, Jan Stenvang, José Moreira, et al.
Breast Cancer Research and Treatment|October 25, 2006
Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cellsLisa B Frankel, Anne E Lykkesfeldt, Jens B Hansen, et al.
Seminars in Cancer Biology|February 26, 2008
The utility of LNA in microRNA-based cancer diagnostics and therapeuticsJan Stenvang, Asli N Silahtaroglu, Morten Lindow, et al.
Cancer Journal (Sudbury, Mass.)|June 1, 2012
The therapeutic potential of microRNAs in cancerStine B Thorsen, Susanna Obad, Niels F Jensen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 24, 2020
Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell lineAsbjørn Nøhr-Nielsen, Sofie Otzen Bagger, Nils Brünner, et al.
Cancers|April 25, 2020
An Explorative Analysis of <i>ABCG2/TOP-1</i> mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 TrialJan Stenvang, Eva Budinská, Eric van Cutsem, et al.
International Journal of Molecular Sciences|September 8, 2017
Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A ReviewDorte Lisbet Nielsen, Jesper Andreas Palshof, Nils Brünner, et al.
Molecular Cancer Therapeutics|June 19, 2007
Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell deathChristina Westmose Yde, Mads Gyrd-Hansen, Anne E Lykkesfeldt, et al.
Breast Cancer Research and Treatment|February 3, 2007
A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancerLouise M Rasmussen, Nurulain T Zaveri, Jan Stenvang, et al.
Cancer Letters|July 17, 2007
Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMATChristina Westmose Yde, Thomas Frogne, Anne E Lykkesfeldt, et al.
Pageof 8